

TRIDENT PHARMACEUTICALS LIMITED

DIRECTORS' STATEMENT FOR THE PURPOSES OF SECTION 644(5) OF THE COMPANIES
ACT 2006

On 24 February 2017, Trident Pharmaceuticals Limited (the **Company**) passed a special resolution to reduce its share capital (**Special Resolution**). The Special Resolution was supported by a solvency statement made by the Company's directors on 24 February 2017 (**Solvency Statement**).

We, being all of the directors of the Company, confirm, for the purposes of section 644(5) of the Companies Act 2006, that the Solvency Statement was:

- (a) made not more than 15 days before the date on which the Special Resolution was passed; and
- (b) provided to members in accordance with section 642(2) of the Companies Act 2006.

Signed by each of the directors on 24 February 2017.

Wendy Margaret Hall

Wendy Margaret Hall

Hanns Martin Lipp

Hanns Martin Lipp



SPE 24/03/2017 #197
COMPANIES HOUSE